New targets for new therapeutic approaches by unknown
François Critical Care 2014, 18:669
http://ccforum.com/content/18/6/669COMMENTARYNew targets for new therapeutic approaches
Bruno François1,2
See related review by Sawa et al., http://ccforum.com/content/18/6/668Abstract
Because of its resistance profiles, Pseudomonas
aeruginosa remains probably one of the challenging
bacteria responsible for ventilator-associated pneumonia
in the ICU. Nevertheless, a much better understanding
of its mechanism of virulence, such as the type 3
secretion system that can also impact on resistance, gives
some opportunities for management improvement. The
most promising approach is probably the production of
monoclonal antibodies that enable not only more
targeted treatments but also development of some
early preemptive approaches at the time of colonization
through real-time diagnosis.play a leading role in the development and persistence ofVentilator-associated pneumonia (VAP) is probably one
of the last infections remaining challenging in the ICU,
unlike sepsis and other ICU-specific infections for which
management is much better defined, and Sawa and col-
leagues bring some new understanding and therapeutic
options [1]. In this specific clinical setting, two microor-
ganisms are predominantly involved – Staphylococcus
aureus and Pseudomonas aeruginosa – both sharing the
same resistance issues and treatment controversies.
Owing to its larger genome, encoding extreme phenotypic
versatility, motility, virulence, and persistence factors as well
as its intrinsic and acquired drug resistance, P. aeruginosa
is possibly the most interesting of the opportunistic
bacteria. In this issue of Critical Care, Sawa and colleagues
demonstrate that P. aeruginosa has the capability of
producing numerous toxins, of which ExoU seems to
play a key role. These authors convincingly illustrate
the potential link between P. aeruginosa virulence and
resistance, with a special emphasis on ExoU-associated
virulence. As a major component of the type 3 secretion
system (T3SS), which is responsible for the injection ofCorrespondence: b.francois@unilim.fr
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months following its publication. After this tim
License (http://creativecommons.org/licenses/
medium, provided the original work is proper
creativecommons.org/publicdomain/zero/1.0/ExoU and various cytotoxic virulence factors into host
cells, PcrV appears to be a promising target for future
VAP prevention agents. Importantly, clinical studies have
previously suggested a relationship between P. aeruginosa
T3SS gene expression in clinical isolates (blood cultures)
and outcome [2]. Additional virulence factors are also
frequently involved in P. aeruginosaVAP. Quorum sensing-
regulated virulence factor rhamnolipids have been identified
in patients with P. aeruginosa VAP and its inhibition
appears to be an alternative therapeutic strategy [3]. Psl is
a serotype-independent exopolysaccharide implicated in
initial colonization and so-called immune evasion [4]. Of
note, these various mechanisms of virulence/resistance
may interact, such as Psl and T3SS expression, and jointly
P. aeruginosa infections, including VAP [5].
While the P. aeruginosa mechanism of action is increas-
ingly decrypted, diagnostic methods have tremendously
improved over the last decade, moving from time-
consuming conventional culture towards real-time bedside
diagnosis. Reverse transcription polymerase chain reaction
is bringing online diagnosis to the clinical grounds and
promises to enable early targeted therapy in the near future.
In addition, continuous technical proceedings facilitate
analysis processes and open new perspectives on the
routine use of these novel diagnostic approaches for a
bedside analysis directly on any lung biological sample
(bronchoalveolar lavage, endotracheal aspirates, and so
forth). Undoubtedly, P. aeruginosa virulence determinants
being better understood, these newly developed diagnostic
techniques promise to simultaneously provide the front-
line intensivist with valuable information on bacterial
virulence and even the drug-resistance profile.
In parallel, VAP management has also improved
dramatically. The major issue of induced resistance by
antibiotics definitely supports the recommended bundles to
prevent VAP, but other benefits are also the prioritization
of targeted antibiotic therapy and reduced treatment
duration [6]. The most promising therapeutic perspective is
the identification of specific P. aeruginosa targets for
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for clinical use and recent publications have demonstrated
their potential clinical value for VAP treatment [7,8]. The
combined early P. aeruginosa infection diagnosis capability
using real-time techniques such as polymerase chain reac-
tion and mAb availability have paved a new road for the
preemptive therapeutic approach in P. aeruginosaVAP and
introduced a paradigm shift in critical care medicine. With
colonization preceding infection (also sometimes referred
to as disease) in nearly all cases, the challenge is now to
confirm the validity of such an approach. We reported
recently convincing results in a phase II trial that tested a
preemptive mAb therapeutic approach targeting PcRv in
ICU P. aeruginosa colonized patients [8]. In addition, given
their complementary roles, a combination of the anti-Psl
and anti-PcrV mAbs as a single drug candidate (MEDI3902;
MedImmune, AstraZeneca, Gaithersburg, MD, USA) could
increase the benefit in a preemptive VAP approach against
P. aeruginosa. To test this hypothesis, trials should
start soon within the ND4BB program (supported by
the Innovative Medicines Initiative) that made the fight
against multiresistant bacteria, and especially P. aeruginosa,
one of its main objectives. A similar preemptive approach
targeting S. aureus alpha toxin with a long half-life
mAb (MEDI4893; MedImmune, AstraZeneca) is already
underway in this program.
In conclusion, it is probably not unrealistic to think
that in the very near future we should be able to rapidly
detect the presence of P. aeruginosa in the lung or lower
respiratory tract and at the same time assess both
drug-resistance and virulence potential for a preemptive
strategy using highly specific mAbs to neutralize key
targets in bacterial virulence, persistence and resistance to
therapy. This theranostic approach focused on new targets
could undoubtedly be the magic bullet to reduce VAP
incidence, as well as the VAP-associated morbidity and
mortality.
Abbreviations
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